After speaking with a legal expert "well-versed in Delaware law," RBC Capital analyst Randall Stanicky says he still has not heard anything that makes him believe Akorn's (AKRX) takeover by Fresenius SE (FSNUY) cannot close. While the outcome remains high risk and debate will continue, Akorn shares have high potential reward relative to the closing deal price of $34 per share, Stanicky tells investors in a research note. The legal expert the analyst spoke to expects a reasonably quick trial from Chancery Judge Laster with the decision likely in July. An appeal would go to the Delaware Supreme Court and could last several months, but expectations are that the trial decision will be "tough" to reverse given this is an issue of fact, the analyst adds. Stanicky has a Sector Perform rating on Akorn shares with a $25 price target.